These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11286309)

  • 21. Long-term management--the way forward?
    Wallentin L
    Clin Cardiol; 2000 Jan; 23 Suppl 1(Suppl):I13-7. PubMed ID: 10680039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery disease.
    Husted S; Becker R; Kher A
    Clin Cardiol; 2001 Jul; 24(7):492-9. PubMed ID: 11444639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The use of low molecular weight heparins in patients with acute ST-elevated myocardial infarction].
    Petrović M; Panić G; Canji T; Srdanović I; Ivanović V; Benc D
    Med Pregl; 2006; 59(9-10):476-81. PubMed ID: 17345826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
    Wang XK; Zhang Y; Yang CM; Wang Y; Liu GY
    Clin Drug Investig; 2006; 26(6):341-9. PubMed ID: 17163268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.
    Antman EM; Louwerenburg HW; Baars HF; Wesdorp JC; Hamer B; Bassand JP; Bigonzi F; Pisapia G; Gibson CM; Heidbuchel H; Braunwald E; Van de Werf F
    Circulation; 2002 Apr; 105(14):1642-9. PubMed ID: 11940541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease.
    Klein W; Buchwald A; Hillis WS; Monrad S; Sanz G; Turpie AG; van der Meer J; Olaisson E; Undeland S; Ludwig K
    Am J Cardiol; 1997 Sep; 80(5A):30E-34E. PubMed ID: 9296467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial.
    Brener SJ; Zeymer U; Adgey AA; Vrobel TR; Ellis SG; Neuhaus KL; Juran N; Ivanc TB; Ohman EM; Strony J; Kitt M; Topol EJ
    J Am Coll Cardiol; 2002 Feb; 39(3):377-86. PubMed ID: 11823073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin.
    Prescrire Int; 1999 Jun; 8(41):77-80. PubMed ID: 10558446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of abciximab combined with dalteparin or unfractionated heparin in high-risk percutaneous coronary intervention in acute myocardial infarction patients.
    Kim W; Jeong MH; Hwang SH; Kim KH; Hong YJ; Ahn YK; Kim W; Cho JG; Park JC; Kang JC
    Int Heart J; 2006 Nov; 47(6):821-31. PubMed ID: 17268117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?
    Kaul S; Shah PK
    J Am Coll Cardiol; 2000 Jun; 35(7):1699-712. PubMed ID: 10841215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study.
    Verheugt FW; Liem A; Zijlstra F; Marsh RC; Veen G; Bronzwaer JG
    J Am Coll Cardiol; 1998 Feb; 31(2):289-93. PubMed ID: 9462569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).
    Montalescot G; Bal-dit-Sollier C; Chibedi D; Collet JP; Soulat T; Dalby M; Choussat R; Cohen A; Slama M; Steg PG; Dubois-Randé JL; Metzger JP; Tarragano F; Guermonprez JL; Drouet L;
    Am J Cardiol; 2003 Apr; 91(8):925-30. PubMed ID: 12686329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
    De Luca G; Marino P
    Am Heart J; 2007 Dec; 154(6):1085.e1-6. PubMed ID: 18035079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HTUPA as a new thrombolytic agent for acute myocardial infarction: a multicenter, randomized study.
    Sun Y; Liu X; Guo L; Pang W; Guo X; Sun Z; Li Z; Cui X; Li H; Tao G; Wang L; Zhou C; Liu Y; Shan H; Wang M; Liu M; Li J; Yin L; Hu D
    Int J Cardiol; 2014 Mar; 172(2):326-31. PubMed ID: 24525155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enoxaparin for the treatment of acute myocardial infarction with persistent ST-segment elevation.
    Rubboli A; Herzfeld I; Maresta A
    Minerva Cardioangiol; 2003 Oct; 51(5):463-70, 470-4. PubMed ID: 14551516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
    Dunn CJ; Sorkin EM
    Drugs; 1996 Aug; 52(2):276-305. PubMed ID: 8841743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial.
    Neuhaus KL; Molhoek GP; Zeymer U; Tebbe U; Wegscheider K; Schröder R; Camez A; Laarman GJ; Grollier GM; Lok DJ; Kuckuck H; Lazarus P
    J Am Coll Cardiol; 1999 Oct; 34(4):966-73. PubMed ID: 10520777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Fraxiparin Anticoagulant Therapy in Myocardial Infarction Study Amsterdam (FATIMA) Study Group.
    Chamuleau SA; de Winter RJ; Levi M; Adams R; Büller HR; Prins MH; Lie KI; Peters RJ
    Heart; 1998 Jul; 80(1):35-9. PubMed ID: 9764056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study.
    Kontny F; Dale J; Abildgaard U; Pedersen TR
    J Am Coll Cardiol; 1997 Oct; 30(4):962-9. PubMed ID: 9316525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial.
    Wallentin L
    Haemostasis; 2000; 30 Suppl 2():108-13; discussion 106-7. PubMed ID: 11251353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.